Breast cancer in Morocco: Synthesizing two decades of national research to inform future action

Abstract

This mini-review synthesizes key evidence on breast cancer in Morocco from major studies published over the past two decades. Moroccan breast cancer is characterized by a distinct profile: A younger median age at diagnosis (45-50 years), a high frequency of advanced-stage disease (stage III or higher in > 60% of hospital-based series), and prolonged diagnostic intervals driven by low symptom awareness and systemic barriers. Pathologically, invasive ductal carcinoma predominates, with hormone receptor-positive/human epidermal growth factor receptor 2-negative being the most common molecular subtype. The evolution towards guideline-concordant, multimodal care in specialized centers, including improved access to targeted therapies, is strongly associated with improved survival, with 5-year disease-free survival rates reaching 80% for appropriately managed patients. However, significant challenges persist, including severe financial toxicity, care access disparities, and gaps in supportive care. Future national strategies must prioritize organized early detection, strengthened patient navigation, universal financial protection, and integrated supportive care to translate research gains into equitable improvements in survival and quality of life.

Keywords: Breast cancer; Morocco; Epidemiology; Diagnosis delay; Therapeutic management; Survival; Quality of life; Health services research

Core Tip: Research over the past twenty years has defined the unique profile of breast cancer in Morocco: A disease of younger women, often diagnosed at an advanced stage. Crucially, evidence now confirms that when patients receive timely, guideline-concordant, multimodal care, including targeted therapies, survival outcomes approach global benchmarks. The synthesis of this work highlights the critical link between standardized care and survival, while exposing persistent systemic challenges like financial toxicity and diagnostic delays. This evidence base provides a clear roadmap for national action, prioritizing early detection programs, financial risk protection, and patient navigation to improve outcomes equitably.